Float Short %

4.94

Margin Of Safety %

Put/Call OI Ratio

0.19

EPS Next Q Diff

0.1

EPS Last/This Y

EPS This/Next Y

-0.1

Price

21.6

Target Price

32.22

Analyst Recom

1.11

Performance Q

3.84

Relative Volume

0.87

Beta

0.84

Ticker: CPRX

21 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2025-01-23	CPRX	22.52	0.14	0.03	3068
2025-01-24	CPRX	22.63	0.13	1.04	3199
2025-01-27	CPRX	22.7	0.14	0.13	3231
2025-01-28	CPRX	22.86	0.14	0.01	3238
2025-01-29	CPRX	23.94	0.14	0.06	3264
2025-01-30	CPRX	23.19	0.12	0.02	3664
2025-01-31	CPRX	22.54	0.13	0.60	3579
2025-02-03	CPRX	22.62	0.18	0.09	4078
2025-02-04	CPRX	23.08	0.17	0.04	4206
2025-02-05	CPRX	23.4	0.17	0.07	4308
2025-02-06	CPRX	23.04	0.17	0.11	4312
2025-02-07	CPRX	22.88	0.17	0.08	4415
2025-02-10	CPRX	22.68	0.17	0.05	4437
2025-02-11	CPRX	22.56	0.17	0.72	4447
2025-02-12	CPRX	22.72	0.17	0.00	4475
2025-02-13	CPRX	23.25	0.17	0.30	4475
2025-02-14	CPRX	23.28	0.17	0.09	4497
2025-02-18	CPRX	22.93	0.17	0.16	4525
2025-02-19	CPRX	22.55	0.17	0.86	4543
2025-02-20	CPRX	22.06	0.18	0.60	4620
2025-02-21	CPRX	21.62	0.19	0.24	4667
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

21 items 1 of 1

21 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-01-23	CPRX	22.51	88.1	120.1	2.04
2025-01-24	CPRX	22.55	88.1	126.4	2.04
2025-01-27	CPRX	22.71	88.1	128.3	2.04
2025-01-28	CPRX	22.83	88.1	127.8	2.04
2025-01-29	CPRX	23.95	88.1	143.2	2.04
2025-01-30	CPRX	23.19	88.1	114.4	2.04
2025-01-31	CPRX	22.53	88.1	115.6	2.04
2025-02-03	CPRX	22.62	88.1	126.7	2.04
2025-02-04	CPRX	23.09	88.1	133.2	2.04
2025-02-05	CPRX	23.37	88.1	130.1	2.04
2025-02-06	CPRX	23.06	88.1	120.6	2.04
2025-02-07	CPRX	22.90	88.1	123.3	2.04
2025-02-10	CPRX	22.76	88.1	123.6	2.04
2025-02-11	CPRX	22.58	88.1	122.9	2.04
2025-02-12	CPRX	22.72	88.1	128.0	2.04
2025-02-13	CPRX	23.22	88.1	134.0	2.04
2025-02-14	CPRX	23.27	88.1	126.0	2.04
2025-02-18	CPRX	22.91	88.1	120.3	2.04
2025-02-19	CPRX	22.53	88.1	119.5	2.04
2025-02-20	CPRX	22.06	88.1	118.3	2.04
2025-02-21	CPRX	21.60	88.1	118.4	2.04
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

21 items 1 of 1

21 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-01-23	CPRX	-8.16	-1.66	6.33
2025-01-24	CPRX	-8.16	-1.66	6.33
2025-01-27	CPRX	-8.16	-1.62	6.33
2025-01-28	CPRX	-8.16	-1.62	6.29
2025-01-29	CPRX	-8.16	-1.62	6.29
2025-01-30	CPRX	-8.16	-1.62	6.29
2025-01-31	CPRX	-8.16	-1.62	6.29
2025-02-03	CPRX	-8.16	-1.13	6.29
2025-02-04	CPRX	-8.16	-1.13	6.29
2025-02-05	CPRX	-8.16	-1.13	6.29
2025-02-06	CPRX	-8.16	-1.13	6.29
2025-02-07	CPRX	-8.16	-1.13	6.29
2025-02-10	CPRX	-8.16	-1.31	6.31
2025-02-11	CPRX	-7.99	-1.31	6.31
2025-02-12	CPRX	-7.99	-1.31	5.10
2025-02-13	CPRX	-7.99	-1.31	5.10
2025-02-14	CPRX	-7.31	-1.31	5.08
2025-02-18	CPRX	-7.31	-1.08	4.94
2025-02-19	CPRX	-9.22	-1.08	4.94
2025-02-20	CPRX	-9.22	-1.08	4.94
2025-02-21	CPRX	-9.22	-1.08	4.94
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

21 items 1 of 1

Last Quarter Act. EPS

0.35

Avg. EPS Est. Current Quarter

0.53

Avg. EPS Est. Next Quarter

0.45

Insider Transactions

-9.22

Institutional Transactions

-1.08

Beta

0.84

Average Sales Estimate Current Quarter

134

Average Sales Estimate Next Quarter

127

Fair Value

31.68

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

12.3

Max Drawdown 5-Year %

-49.9

Target Price

32.22

P/E

18.45

Forward P/E

PEG

0.45

P/S

5.6

P/B

3.9

P/Free Cash Flow

13.71

EPS

1.17

Average EPS Est. Cur. Y

2.04

EPS Next Y. (Est.)

1.94

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

31.01

Relative Volume

0.87

Return on Equity vs Sector %

2.4

Return on Equity vs Industry %

EPS 1 7Days Diff

0.1

EPS 1 30Days Diff

0.09

EBIT Estimation

118.4

Catalyst Pharmaceuticals, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 167

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.

stock quote shares CPRX – Catalyst Pharmaceuticals, Inc. Stock Price stock today

news today CPRX – Catalyst Pharmaceuticals, Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch CPRX – Catalyst Pharmaceuticals, Inc. yahoo finance google finance

stock history CPRX – Catalyst Pharmaceuticals, Inc. invest stock market

stock prices CPRX premarket after hours

ticker CPRX fair value insiders trading

Investment involves risk. As a general rule, you should only trade in financial products that you are familiar with and understand the risk associated with them. The risk warning described in each financial product below is not exhaustive, you should carefully consider your investment experience, financial situation, investment objective, risk tolerance level and consult your independent financial adviser as to the suitability of your situation prior making any investment.

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: CPRX

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Get Started

About

Last Quarter Act. EPS

Average EPS Est. Cur. Y